Patch-clamp electrophysiology is an important technique utilized for studying ion channels, integral membrane proteins, which allow ion current flow across the cell membrane. Ion channels are important pharmacological targets, as they are involved in almost all physiological processes and their malfunction can cause many diseases.
The automated patch clam technique was developed in the late 1990s and early 2000s. This technique involves the replacing of patch-clamp pipette with a planar substrate, which makes the experiments easier to perform. The automated patch clamp system provides increased throughput and enhanced simplicity, which has made ion-channel drug discovery process easier.
The global automated patch clamp system market is estimated to be valued at US$ 412.01 million in 2020 and is expected to exhibit a CAGR of 6.9% over the forecast period (2020-2027).
Figure 1. Global Automated Patch Clamp System Market Share (%) in Terms of Value, By Region, 2020
Technological advancements in automated patch clamp systems is expected to propel the market growth over the forecast period
Over the last decade, market players such as Nanion Technologies GmbH and Sophion Bioscience A/S have developed high-quality miniaturized amplifiers, which led to the development of high-throughput patch-clamp instruments. These instruments can perform potential recordings from 384 wells simultaneously. Hence, development of such technologies for automated patch clamping is expected to boost growth of the global automated patch clamp system market over the forecast period.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2019 | Market Size in 2020: | US$ 412.01 Mn |
| Historical Data for: | 2016 to 2019 | Forecast Period: | 2020 to 2027 |
| Forecast Period 2020 to 2027 CAGR: | 6.9% | 2027 Value Projection: | US$ 412.01 Mn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Sophion Bioscience A/S, Nanion Technologies GmbH, NeoBiosystems, Inc., Multi Channel Systems MCS GmbH, Fluxion Biosciences, Molecular Devices, LLC, Scitech Korea Inc., and HEKA Elektronik GmbH |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Increasing product launches by market players is expected to drive the market growth over the forecast period
Companies involved in manufacturing automated patch clamp systems are constantly updating and improving their instrumentation and assays for automated patch clamp techniques in order to make the automated patch clamp systems more affordable and accessible to a wider audience, which is expected to boost the market growth over the forecast period. For instance, in October 2019, Nanion Technologies GmbH launched Port-a-Patch mini, a small and affordable patch-clamp instrument.
Global Automated Patch Clamp System Market – Impact of Coronavirus (Covid-19) Pandemic
The coronavirus disease (COVID-19) pandemic is the most recent outbreak, which was first reported on December 31, 2019 in Wuhan, China. The World Health Organization declared coronavirus disease (COVID-19) as a pandemic on March 11, 2020.
According to the Coronavirus Disease (COVID-19) Weekly Epidemiological Update by the World Health Organization, over 53.7 million cases and 1.3 million deaths due to coronavirus disease (COVID-19) were reported up till November 15, 2020 across the globe.
According to the Coronavirus Disease (COVID-19) Weekly Epidemiological Update by the World Health Organization, the coronavirus disease (COVID-19) cases in different regions reported up till November 15, 2020 are as follows:
| WHO Regions | New cases in last 7 days | Cumulative cases |
| The Americas | 1,450,998 |
22,960,102 |
| South-east Asia | 373,786 |
10,015,731 |
| Europe | 1,840,086 |
15,047,248 |
| Africa | 40,990 |
1,398,935 |
| Eastern Mediterranean | 238,390 |
3,545,801 |
| Western Pacific | 32,973 |
798,170 |
Hence, due to dynamically rising cases of COVID-19, the market players are observing delays in installation of automated patch clamp systems, which is expected to limit the market growth during the forecast period. For instance, in March 2019, Sophion Bioscience A/S announced that some of its users have postponed the installation of new systems due to travel restrictions.
Automated Patch Clamp System Market: Restraints
However, high cost of automated patch clamp systems and lack of expertise for the installation of automated patch clamp systems are expected to hinder growth of the global automated patch clamp system market during the forecast period.
Key Players
Major players operating in the global automated patch clamp system market include Sophion Bioscience A/S, Nanion Technologies GmbH, NeoBiosystems, Inc., Multi Channel Systems MCS GmbH, Fluxion Biosciences, Molecular Devices, LLC, Scitech Korea Inc., and HEKA Elektronik GmbH.
The techniques available for automated patch clamping are divided into three categories: the automated glass pipette-based patch clamp, the micro-fabricated planar electrode-based patch clamp, and automated TEVC on Xenopus oocytes. The use of automated patch clamp system has increased significantly to perform cardiac safety screening. For instance, automated patch clamp systems such as IonFlux Mercury HT manufactured by Fluxion Biosciences have been used for cardiac safety profiling (hERG).
Market players are focusing on launching advanced automated patch clamp systems, in order to strengthen their market presence and expand their product portfolio, which is expected to boost growth of the global automated patch clamp system market over the forecast period. For instance, in September 2020, Fluxion Biosciences launched IonFlux Mercury Ultra, a high-throughput automated patch clamp system.
Market Dynamics
Increasing research and development of therapeutic drugs and medical devices is expected to drive growth of the automated patch clamp system market over the forecast period. According to the United Nations Educational, Scientific and Cultural Organization (UNESCO), November 2016, an estimated US$ 1.7 trillion was spent on research and development for various medical applications, globally. Moreover, the U.S. Food and Drug Administration (FDA) and its Center for Drug Evaluation and Research (CDER) approved around 59 novel drugs in 2018 compared to 46 approvals of new molecule entities in 2017.
Moreover, according to the Pharma R&D Annual Review, 2019, an estimated number of drugs under pipeline in 2019 was around 16,181, while in 2018, it was around 15,267, resulting in an overall pipeline growth by 6% in 2018.
Key features of the study:
Detailed Segmentation:
“*” marked represents similar segmentation in other categories in the respective section.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients